Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412

Blood

Volumn 106, Issue 2, 2005, Pages 721-724

  Growney, Joseph D ^b   Clark, Jennifer J ^b   Adelsperger, Jennifer ^b   Stone, Richard ^b   Fabbro, Doriano ^b   Griffin, James D ^b   Gilliland, D Gary ^a  

^a Karp Family Research Laboratories   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; INTERLEUKIN 3; MIDOSTAURIN; PROTEIN TYROSINE KINASE INHIBITOR; STAT5 PROTEIN; STEM CELL FACTOR RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CELL TRANSFORMATION; CONTROLLED STUDY; DIAGNOSTIC VALUE; GASTROINTESTINAL TUMOR; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAST CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 22144455380     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-12-4617     Document Type: Article

References (25)

1. Broudy VC. Stem cell factor and hematopoiesis. Blood. 1997;90:1345-1364.
2. Furitsu T, Tsujimura T, Tono T, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest. 1993;92:1736-1744.
3. Tsujimura T, Furitsu T, Morimoto M, et al. Substitution of an aspartic acid results in constitutive activation of c-kit receptor tyrosine kinase in a rat tumor mast cell line RBL-2H3. Int Arch Allergy Immunol. 1995;106:377-385.
4. Pignon JM, Giraudier S, Duquesnoy P, et al. A new c-kit mutation in a case of aggressive mast cell disease. Br J Haematol. 1997;96:374-376.
5. Beghini A, Peterlongo P, Ripamonti CB, et al. c-Kit mutations in core binding factor leukemias. Blood. 2000;95:726-727.
6. Beghini A, Larizza L, Cairoli R, Morra E. c-Kit activating mutations and mast cell proliferation in human leukemia. Blood. 1998;92:701-702.
7. Beghini A, Magnani I, Ripamonti CB, Larizza L. Amplification of a novel c-Kit activating mutation Asn(822)-Lys in the Kasumi-1 cell line: a t(8;21)-Kit mutant model for acute myeloid leukemia. Hematol J. 2002;3:157-163.
8. Gari M, Goodeve A, Wilson G, et al. c-Kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. Br J Haematol. 1999;105:894-900.
9. Duensing A, Heinrich MC, Fletcher CD, Fletcher JA. Biology of gastrointestinal stromal tumors: KIT. Cancer Invest. 2004;22:106-116.
10. Lux ML, Rubin BP, Biase TL, et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol. 2000;156:791-795.
11. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577-58O.
12. Longley BJ Jr, Metcalfe DD, Tharp M, et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci USA. 1999;96:1609-1614.
13. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472-480.
14. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with gastrointestinal stromal tumor. J Clin Oncol. 2003;21:4342-4349.
15. Pardanani A, Elliott M, Reeder T, et al. Imatinib for systemic mast-cell disease. Lancet. 2003;362:535-536.
16. Ma Y, Zeng S, Metcalfe DD, et al. The c-KIT mutation, causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood. 2002;99:1741-1744.
17. Zermati Y, De Sepulveda P, Feger F, et al. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene. 2003;22:660-664.
18. Akin C, Brockow K, D'Ambrosio C, et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol. 2003;31:686-692.
19. Frost MJ, Ferrao PT, Hughes TP, Ashman LK. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant DB16VKit is resistant. Mol Cancer Ther. 2002;1:1115-1124.
20. Fabbro D, Ruetz S, Bodis S, et al. PKC412-a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des. 2000;15:17-28.
21. Cools J, Stover EH, Boulton CL, et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease. Cancer Cell. 2003;3:459-469.
22. Sternberg DW, Tomasson MH, Carroll M, et al. The TEL/PDGFbetaR fusion in chronic myelomonocytic leukemia signals through STAT5-dependent and STAT5-independent pathways. Blood. 2001;98:3390-3397.
23. Tuveson DA, Willis NA, Jacks T, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene. 2001;20:5054-5058.
24. Casteran N, De Sepulveda P, Beslu N, et al. Signal transduction by several KIT Juxtamembrane domain mutations. Oncogene. 2003;22:4710-4722.
25. Ning ZQ, Li J, Arceci RJ. Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells. Blood. 2001;97:3559-3567.